ISSCR News
Researchers Identify 166 Human Pluripotent Stem Cell Lines Available for Use in Clinical Applications
To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have entered early developmental pipelines. For off-the-shelf (allogeneic) products, the identification and selection of the right hPSC line early on during this process is of utmost importance as failure to do so may delay or completely stall product development. While developers acknowledge the importance of this issue, a comprehensive, accessible listing of globally available hPSC lines to inform cell line selection for clinical use has been elusive until now.
Insights Into Dry Eyes Gained from Stem cell-derived Tear Glands
An estimated 5-15% of people have problems with dry eyes, with symptoms including eye redness, stinging, or burning sensation, and eye fatigue. Dry eye disease (DED) occurs when the eyes’ tear glands produce insufficient or poor-quality tears which can be due to allergy or autoimmune disease, hormonal changes, aging, etc. When left untreated, DED can increase the risk of eye infections and abrasion damage to the ocular surface, which may impair vision.
The ISSCR Announces Poster Award Winners from Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind
Four early career scientists were recognized for their outstanding poster presentations at the ISSCR International Symposium held in Cambridge, USA 11-12 December 2025. The awards are sponsored by WiCell.
Non-opioid ‘Pain Sponge’ Therapy Halts Cartilage Degeneration and Relieves Chronic Pain
The announcement was made at the International Society for Stem Cell Research (ISSCR) Symposium Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind
Session Highlight
SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, unveiled new data today on a novel approach to chronic pain management and joint tissue preservation. The data highlights SN101, a first-in-class induced pluripotent stem cell (iPSC)-derived therapy.
The ISSCR Opens Sold-Out Symposium Showcasing Momentum, Innovation, and New Clinical Data in PSC-Derived Cell Therapies
The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating PSC-Derived Cell Therapies: Starting with the End in Mind, taking place 11-12 December at the Hyatt Regency Boston Cambridge. The meeting convenes a capacity audience of 360 global experts, alongside an at-capacity roster of biotech and pharma sponsors and exhibitors – underscoring the strength, interest and continued momentum in cell therapy development despite recent industry contraction.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .